Insmed Announces FDA Not Holding Advisory Committee Meeting for Brensocatib NDA
Insmed Incorporated (NASDAQ: INSM) announced on February 24, 2025 that the U.S. Food and Drug Administration (FDA) does not currently plan to hold an advisory committee meeting to discuss the company’s New Drug Application (NDA) for brensocatib, intended for the treatment of patients with non-cystic fibrosis bronchiectasis. The update came as part of the FDA’s […]
Insmed Incorporated (NASDAQ: INSM) announced on February 24, 2025 that the U.S. Food and Drug Administration (FDA) does not currently plan to hold an advisory committee meeting to discuss the company’s New Drug Application (NDA) for brensocatib, intended for the treatment of patients with non-cystic fibrosis bronchiectasis. The update came as part of the FDA’s […]
